Abstract:Objective: To evaluate the effects of cyclooxygenase(COX)-2 inhibitor celecoxib on COX-2 gene expression and cisplatin chemosensitivity in human lung adenocarcinoma A549 cell line with overexpressed COX-2. Methods: The inhibitory effects of celecoxib or celecoxib combined with anticancer drug cisplatin on the proliferation of human lung adenocarcinoma A549 cell line were detected by MTT. The cell growth inhibition and cell cycle apoptosis were assessed by MTT and flow cytometry. COX-2 gene expression was detected by Western blot. Results: There was a dose-dependent and time-dependent(0-100 μmol/L)inhibition of cell proliferation induced by celecoxib. IC50 value of celecoxib in A549 was 30.9 μmol/L 72 hours after the treatment. The cell growth inhibition rate of A549 was(14.17 ± 1.39)%, (19.11 ± 1.45)% and (38.16 ± 1.67)% in cisplatin(0.5 mg/L)group and celecoxib groups(12.5 μmol/L, 25 μmol/L) respectively. When combined treatment of celecoxib (12.5 μmol/L, 25 μmol/L) and cisplatin (0.5 mg/L)was used, the cell growth inhibition rate was (33.75 ± 2.02)% and (49.64 ± 2.19)%, respectively. The differences were significant (P < 0. 001). The apoptotic rate of A549 cells induced by cisplatin(0.5 mg/L)or celecoxib(12.5 μmol/L, 25 μmol/L) was(1.74 ± 0.77)%, (0.26 ± 0.02)% or (2.75 ±0.13)%, respectively. The apoptotic rate was (6.49 ± 0.88)% and (10.59 ± 1.22)% after combined treatment of celecoxib (12.5 μmol/L, 25 μmol/L) and cisplatin(0.5 mg/L) respectively. High-dose celecoxib (>50 μmol/L) can suppress COX-2 gene expression. Conclusion: The anticancer effects of a selective COX-2 inhibitor celecoxib partly depend on COX-2 expression in the cells. Combined treatment with celecoxib plus cisplatin shows significantly greater inhibitory effects on the growth of human lung adenocarcinoma A549 cell line.

[Effects of Nonsteroidal Anti-Inflammatory Drug Celecoxib on Expression of Cyclooxygenase-2 (COX-2) in Ovarian Carcinoma Cell].

Expression of COX-2 in Primary Ovarian Carcinoma and the Effects of Celecoxib on the Cell Proliferation of the Human Ovarian Carcinoma Cell Line A2780

[Effect of Selective Cyclooxygenase-2 Inhibitor Celebrex on Expression of Vascular Endothelial Growth Factor (VEGF) in Pancreatic Carcinoma].

Cyclooxygenase-2 Induces Angiogenesis in Pancreatic Cancer Mediated by Prostaglandin E-2

Impact of the Selective Cyclooxygenase-2 Inhibitor Celebrex on Angiogenesis in Pancreatic Carcinoma

Inhibitory effect of celecoxib on proliferation,invasion and VEGF expression of ovarian carcinoma SKOV3 cells

Effect of celecoxib on hepatic and renal functions in rats with mammary carcinoma

Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway.

Apoptosis Induced by Celecoxib Eombinated with Cisplatin in Human Osteosarcoma Cell Line MG-63 Via Down-Regulation of PI3K/Akt

Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry.

Cyclooxygenase-Independent Effects of Aspirin on Ht-29 Human Colon Cancer Cells, Revealed by Oligonucleotide Microarrays

Effects of cyclooxygenase-2 inhibitor celecoxib on cyclooxygenase-2 gene expression and cisplatin chemosensitivity in human lung adenocarcinoma A549 cell line

Celecoxib in the Histological Grade of Chemically Induced Mammary Tumor in Rats

The effect of COX-2 inhibitor on bladder cancer

Celecoxib Enhances Anticancer Effect of Cisplatin and Induces Anoikis in Osteosarcoma Via PI3K/Akt Pathway.

Effects of a selective cyclooxygenase 2 inhibitor celecoxib on the proliferation and apoptosis of human prostate cancer cell line PC-3]

Experimental Study on Inhibitive Effect of a Non-Steroidal Anti-Inflammatory Drug,celecoxib,on Lung Adenocarcinoma

Assessment of celecoxib pharmacodynamics in pancreatic cancer

[Short-Term Preoperative Treatment of Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, on E-cadherin Expression in Gastric Carcinoma Tissues].

Effect of Celecoxib on Proliferation, Moving and Invasiveness of Glioma Cells

Targeting COX-2 potently inhibits proliferation of cancer cells in vivo but not in vitro in cutaneous squamous cell carcinoma